# Ph II Early BC Pre-Surgical Biologic Study

> **NCT00637026** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 65 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00637026
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2009-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637026, "Ph II Early BC Pre-Surgical Biologic Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00637026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*